ARWR (Arrowhead Pharmaceuticals) Other Long-Term Liabilities: $392.5 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARWR Arrowhead Pharmaceuticals Inc ARWR
49 GF Score
Price $87.50
GF Value $56.76
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Other Long-Term Liabilities?

Arrowhead Pharmaceuticals ARWR -2.20% 49 Other Long-Term Liabilities is $392.5 Mil as of Jun. 2026. GuruFocus rates ARWR with a GF Score™ of 49/100 and a GF Value™ of $56.76 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Arrowhead Pharmaceuticals's other long-term liabilities for the quarter that ended in Jun. 2026 was $392.5 Mil.

Arrowhead Pharmaceuticals's quarterly other long-term liabilities increased from Dec. 2025 ($375.0 Mil) to Mar. 2026 ($383.8 Mil) and increased from Mar. 2026 ($383.8 Mil) to Jun. 2026 ($392.5 Mil).

Arrowhead Pharmaceuticals's annual other long-term liabilities increased from Sep. 2023 ($268.3 Mil) to Sep. 2024 ($341.4 Mil) and increased from Sep. 2024 ($341.4 Mil) to Sep. 2025 ($367.4 Mil).

Arrowhead Pharmaceuticals Other Long-Term Liabilities Related Terms

Arrowhead Pharmaceuticals Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals Other Long-Term Liabilities Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 268.33 341.36 367.40

Arrowhead Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 360.25 367.40 375.00 383.83 392.51
ARWR
49GF Score
Arrowhead Pharmaceuticals Inc ARWR
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arrowhead Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $392.5 Mil mean?
Arrowhead Pharmaceuticals (ARWR) has a Other Long-Term Liabilities of $392.5 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Arrowhead Pharmaceuticals and its competitors.
Is Arrowhead Pharmaceuticals' Other Long-Term Liabilities too high?
Arrowhead Pharmaceuticals' current Other Long-Term Liabilities is $392.5 Mil. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Other Long-Term Liabilities compare to AXSM and MDGL?
Arrowhead Pharmaceuticals' Other Long-Term Liabilities of $392.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Arrowhead Pharmaceuticals and its competitors. Arrowhead Pharmaceuticals's current Other Long-Term Liabilities is $392.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals (ARWR) is currently considered Significantly Overvalued. The stock's GF Value™ is $56.76, compared to a current price of $87.50 — trading 54.2% above its estimated fair value. The current Other Long-Term Liabilities is $392.5 Mil. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (ARWR), the current Other Long-Term Liabilities is $392.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arrowhead Pharmaceuticals (ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of $87.50 is trading 54.2% above its estimated GF Value™ of $56.76. GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ARWR:

  • Other Long-Term Liabilities: $392.5 Mil
  • GF Value™: $56.76 vs. price of $87.50 (54.2% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score

Get the complete analysis for ARWR

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$87.50
Price
$56.76
GF Value